Amneal receives first product approval in china

Bridgewater, n.j.--(business wire)--amneal pharmaceuticals, inc. (nyse: amrx) (“amneal” or the “company”) today announced it has received its first product approval in china. sevelamer carbonate was approved and is expected to launch shortly. in addition, the company expects to launch oseltamivir phosphate in china this year as well, upon approval. in total, amneal has 6 products pending review in china with more product registrations planned over time. since 2019, the company has collaborated.
AMRX Ratings Summary
AMRX Quant Ranking